Home Therapy in New Jersey

SOLUtion Medical is a specialty pharmaceutical and medical device company developing integrated drug-device combination products focused on reconstitution and simplified drug delivery. The company's flagship platform centers on the TwistJECT® line—a dual-chamber prefilled syringe and auto-injector system that simplifies reconstitution of powder and diluent formulations. Initially developed to address adrenal crisis, TwistJECT® compresses a 14-step manual injection process into intuitive, easy-to-use delivery mechanisms suitable for patients, caregivers, and clinicians across home and healthcare settings. The dual-chamber technology enables both manual prefilled syringe and automated auto-injector variants. SOLUtion's development approach emphasizes patient and caregiver input throughout the design process, partnering with institutions including Children's Hospital of Philadelphia and Pituitary Foundations (UK and Ireland). The company is expanding its reconstitution platform beyond adrenal crisis into mental health and fertility indications. Products are designed to reduce treatment burden and hospitalization rates; data cited on the site show adrenal crisis hospitalization costs averaging $28K and increased ICU admission risk when treatment is delayed. The company maintains a fully integrated supply chain for drug-device development and manufacturing. Devices are not yet FDA-approved; the site indicates current products are in development/regulatory pathways.

KORU Medical Systems, Inc. manufactures and distributes subcutaneous infusion systems designed for patient autonomy and home-based therapeutic administration. The company's primary product portfolio includes the Freedom™ Infusion System family—specifically the Freedom60® and FreedomEDGE® syringe infusion pumps—along with complementary disposable accessories including High-Flo™ Subcutaneous Safety Needle Sets and Precision™ Flow Rate Tubing. These devices are FDA-cleared (510(k) summaries K200176 for Freedom and K214045 for FreedomEDGE) and indicated for subcutaneous delivery of immunoglobulin and other therapeutics, including RYSTIGGO® in the US market. KORU's systems are designed to enable patient administration of medicine in alignment with the body's natural physiological processes while allowing treatment in home and non-clinical settings. The company provides clinical training, nursing support, and patient education resources to ensure safe device use. Target markets include patients requiring chronic subcutaneous infusion therapy, immunology practices, hospital infusion centers, and home healthcare providers. KORU emphasizes patient empowerment, ease of use, and compatibility with established subcutaneous delivery protocols.

Bio Compression Systems, Inc. is a US-based manufacturer of pneumatic compression devices designed to treat lymphatic and circulatory disorders. The company specializes in sequential compression pumps that employ non-peristaltic action to mimic the body's natural lymphatic function, reducing swelling, decreasing pain, and improving range of motion and mobility. Product applications include lymphedema management, lipedema, venous and arterial insufficiency, wound care support, DVT prophylaxis, post-operative recovery, sports medicine, phlebolymphedema, and peripheral arterial disease (PAD). Bio Compression devices are engineered for both clinical hospital settings and home use, featuring sleek, quiet, lightweight, and portable designs with user-friendly operation. The company markets to healthcare providers, durable medical equipment (DME) suppliers, physical therapists, and individual patients. Multiple product lines (SC-2004-OC, SC-3008-DL, SC-3004-DL, SC-2008-OC, VascuEase, IC-BAP, IC-1545) serve different anatomical regions and clinical needs. The company also offers compression garments as complementary products. Bio Compression maintains a direct sales model with patient education and clinical support; patient testimonials document significant reductions in limb circumference, improved functional mobility, reduced pain, and enhanced quality of life. Manufacturing and customer support are located in Moonachie, NJ.

CozeeCoo, LLC manufactures the CozeeCoo®, a wearable infant positioning blanket and FDA-registered Class I medical device designed to prevent self-interference at the chest and above in infants aged newborn to 15 months. The product is engineered to deter hand contact with post-procedure medical sites, medical devices, topical medications, and areas affected by severe skin irritation or repetitive hand contact (such as eczema, cleft lip/palate recovery, or surgical sites). Made from Global Organic Textile Standard (GOTS) certified 100% organic cotton with hypoallergenic properties (free from nickel, toxic dyes, bleach, formaldehyde, and fragrances), the garment is washer, iron, and dryer safe. The CozeeCoo® features mobile arms that allow limb and body movement while restricting access to the chest area, and is suitable for use during sleep, diaper changes, and in standard car seats. The device is labeled with Unique Device Identification (UDI) barcodes for improved patient safety and surveillance. CozeeCoo® is FDA-listed and registered in the United States; sold internationally as a wearable baby blanket. The company offers multiple size options (Newborn/Preemie through 12-15 months) based on WHO child growth standards. Eligible for HSA/FSA/HRA reimbursement with a Letter of Medical Necessity. Fulfillment center located in New Jersey; ships globally via DHL, UPS, and USPS. Product launched March 2021; recognized as a TIME Best Invention 2023. Healthcare facility partnerships available; product is stocked in pediatric hospitals across the United States.

Lympha Press USA manufactures pneumatic compression therapy systems and garments for at-home management of lymphedema, chronic venous insufficiency, and lipedema. The company's primary product line includes the Optimal Plus™ digitally-connected compression pump system, which delivers clinically proven sequential compression therapy with flexible, condition-tailored settings. Product offerings encompass compression pumps, lower body garments (Lympha Pants), upper body garments (Lympha Jacket), and the LymphaPod® portable compression device. The company emphasizes patient compliance and ease of use, reporting high user satisfaction and sustained treatment adherence rates. Lympha Press targets both individual patients seeking home-based therapy and clinicians managing patient care. The platform integrates digital connectivity to support remote monitoring and therapy adjustments. All products are designed for long-term home use and daily wear. The company maintains a patient education community and clinician support resources to optimize outcomes for chronic lymphatic and venous conditions affecting approximately 10 million Americans.

Upstep LLC manufactures custom-molded orthotic insoles (inserts) designed to address foot pain and provide arch support for various lifestyles and clinical conditions. The company operates a direct-to-consumer model where customers complete an online questionnaire, receive an impression kit by mail, imprint their feet, and return the kit for custom insole fabrication within 12–18 business days. Products are designed by an in-house team of podiatrists led by Chief Medical Officer Philip Wells, with over 25 years of experience and more than 500,000 orthotics produced. Upstep offers specialized insole lines for different activity levels (On My Feet All Day for extended standing, Normal Everyday Activity for general use) and sport-specific options (running, multi-sport, hiking, fitness walking, gym, and golf). All custom insoles are FSA/HSA-eligible, include a 180-day money-back guarantee, free remakes if adjustments are needed, and 1-year warranty on the top layer. The company maintains customer 3D foot imaging and order data for 5 years to facilitate reorders without re-impression. The product is manufactured using advanced materials and technology tailored to individual foot anatomy, age, lifestyle, activity type, and any diagnosed podiatric conditions. Upstep accepts major payment methods including Klarna (interest-free installment payments) and offers free shipping and returns.

JOGO Health is a digital therapeutics company specializing in FDA-registered Class II EMG biofeedback systems for pain and neuromuscular disorder management. The platform integrates wearable sensors with advanced AI to leverage neuroplasticity, delivering non-invasive, medication-free virtual rehabilitation. Founded on research by Dr. Joseph Brudny (NYU) and Dr. Gordon Silverman (Rockefeller University), JOGO combines Electromyography biofeedback, Pain Neuroscience Education, Pain Reprocessing Therapy, and physical therapy. Clinical trials at Brigham and Women's Hospital (Harvard) and Mayo Clinic demonstrated superior outcomes versus opioids for chronic pain and superiority over standard care for neuromuscular disorders. The platform enables hybrid or fully virtual tele-rehabilitation, allowing home-based therapy. Medicare and major commercial payers cover JOGO for migraine, tension-type headache, cancer pain, urinary incontinence, pelvic pain, fecal incontinence, chronic constipation, stroke recovery, and neurorehabilitation. Indicated conditions include Parkinson's, Essential Tremor, cerebral palsy, Bell's palsy, spinal cord injury, and multiple sclerosis.

NeuroMetrix, Inc. is a neurotechnology company specializing in non-invasive medical devices for diagnosing and treating pain and neurological disorders. The company develops point-of-care neuropathy diagnostic tests and FDA-approved wearable neurostimulation devices. Its Quell® platform is a wearable neuromodulator designed for chronic pain management and fibromyalgia symptom reduction. DPNCheck provides rapid nerve conduction testing for peripheral neuropathy evaluation. NeuroMetrix targets healthcare professionals including endocrinologists and podiatrists, as well as direct consumers. Founded in 1996 and based in Woburn, Massachusetts, the company is a wholly-owned subsidiary of electroCore, Inc. and is publicly traded on Nasdaq (NURO). The company emphasizes innovation in digital medicine and neurostimulation through clinical feedback and research.